• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacoepidemiology and drug safety >High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic.
【24h】

High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic.

机译：在公立医院诊所中，不良反应发生率高，患者对降脂药物联合用药的不了解。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: Examine use, patient awareness and outcomes of concurrent cerivastatin and gemfibrozil in a public hospital clinic system 2 weeks following cerivastatin withdrawal. METHODS: Electronic pharmacy records for cerivastatin prescriptions for 1 year preceding withdrawal were downloaded and linked to gemfibrozil prescriptions. Patients with concurrent prescriptions were surveyed for current use, awareness of withdrawal/warnings, adverse effects and creatine phosphokinase (CK) results. RESULTS: From August 2000 to August 2001, 29,377 prescriptions for cerivastatin were dispensed for 10,780 unique patients; 211 (2%) also received gemfibrozil. Prescription time frames for the two drugs overlapped for 67 patients. Interview of 47 patients revealed 35 actually taking both. 18/35 (51.4%) were still taking both drugs 2 weeks after market-withdrawal of cerivastatin. Only 7/46 (21.2%) had 'heard the news' about withdrawal. 19/46 (41.3%) described muscle-related symptoms; nine reported severe symptoms. Only 13(28.3%) had CK monitoring. 5/8 symptomatic patients monitored had CK values > 200 U/L. (> 1000 U/L in two cases.) CONCLUSIONS: Despite escalating labeled warnings, nearly 2% of patients prescribed cerivastatin received gemfibrozil prescriptions, 1/3 concurrently. Most were still taking this combination 2 weeks after cerivastatin withdrawal and unaware of publicized warnings. Nearly half experienced muscle-related symptoms. More reliable methods for preventing prescription/dispensing of interacting medications and alerting patients about drug recalls are warranted.
机译：目的：在撤出西立伐他汀2周后，在公共医院诊所系统中检查并用西立伐他汀和吉非贝齐的使用，患者意识和结局。方法：下载撤药前一年的西立伐他汀处方药的电子药房记录，并将其链接到吉非贝齐处方药。调查了同时开处方的患者的当前使用情况，戒断/警告意识，不良反应和肌酸磷酸激酶（CK）结果。结果：从2000年8月至2001年8月，共向10,780名独特患者分配了29,377份西立伐他汀处方; 211（2％）也接受了吉非贝齐。两种药物的处方时限重叠为67名患者。对47位患者的访谈显示，有35位患者同时服用了这两种药物。 cerivastatin退出市场后2周，仍有18/35（51.4％）的人同时服用两种药物。只有7/46（21.2％）的人听说过退出的消息。 19/46（41.3％）描述了与肌肉相关的症状;九例报告严重症状。只有13个（28.3％）进行了CK监视。监测的5/8有症状患者的CK值> 200 U / L。 （在两种情况下> 1000 U / L。）结论：尽管警告贴标不断升级，但近2％的处方西立伐他汀的患者同时接受了吉非贝齐处方，同时接受了1/3。停用西立伐他汀2周后，大多数患者仍在服用这种组合药物，并且未意识到公开的警告。近一半经历了与肌肉相关的症状。必须采用更可靠的方法来防止相互作用的药物开出处方/分发，并提醒患者有关药物召回的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号